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Abstract
Hypertension has a major associated risk for organ damage and mortality, which is further heightened in patients
with prior cardiovascular (CV) events, comorbid diabetes mellitus, microalbuminuria and renal impairment. Given
that most patients with hypertension require at least two antihypertensives to achieve blood pressure (BP) goals,
identifying the most appropriate combination regimen based on individual risk factors and comorbidities is
important for risk management. Single-pill combinations (SPCs) containing two or more antihypertensive agents
with complementary mechanisms of action offer potential advantages over free-drug combinations, including
simplification of treatment regimens, convenience and reduced costs. The improved adherence and convenience
resulting from SPC use is recognised in updated hypertension guidelines. Despite a wide choice of SPCs for
hypertension treatment, clinical evidence from direct head-to-head comparisons to guide selection for individual
patients is lacking. However, in patients with evidence of renal disease or at greater risk of developing renal
disease, such as those with diabetes mellitus, microalbuminura and high-normal BP or overt hypertension,
guidelines recommend renin-angiotensin system (RAS) blocker-based combination therapy due to superior
renoprotective effects compared with other antihypertensive classes. Furthermore, RAS inhibitors attenuate the
oedema and renal hyperfiltration associated with calcium channel blocker (CCB) monotherapy, making them a
good choice for combination therapy. The occurrence of angiotensin-converting enzyme (ACE) inhibitor-induced
cough supports the use of angiotensin II receptor blockers (ARBs) for RAS blockade rather than ACE inhibitors. In
this regard, ARB-based SPCs are available in combination with the diuretic, hydrochlorothiazide (HCTZ) or the
calcium CCB, amlodipine. Telmisartan, a long-acting ARB with preferential pharmacodynamic profile compared with
several other ARBs, and the only ARB with an indication for the prevention of CV disease progression, is available
in two SPC formulations, telmisartan/HCTZ and telmisartan/amlodipine. Clinical studies suggest that in CV high-risk
patients and those with evidence of renal disease, the use of an ARB/CCB combination may be preferred to ARB/
HCTZ combinations due to superior renoprotective and CV benefits and reduced metabolic side effects in patients
with concomitant metabolic disorders. However, selection of the most appropriate antihypertensive combination
should be dependent on careful review of the individual patient and appropriate consideration of drug
pharmacology.
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Hypertension is a highly prevalent disease with a major
associated risk for cardiovascular (CV) morbidity and
mortality [1-3]. The majority of patients with hyperten-
sion require more than one antihypertensive agent to
achieve and maintain guideline-recommended blood
pressure (BP) goals [4-8]. Identifying the most appro-
priate combination therapy for each patient based on
individual risk factors and comorbidities is important
for risk management. Increasingly, single-pill combina-
tions (SPCs) containing two or more antihypertensive
agents with complementary mechanisms of action are
available. These offer potential advantages, including
simplification of treatment regimens, more convenient
drug administration and reduced healthcare costs
[5,9,10]. Evidence from meta-analyses has shown that
the use of antihypertensive SPCs compared with corre-
sponding free-drug combinations is associated with sig-
nificantly greater rates of treatment adherence to
medication and potential advantages in terms of BP
improvements and adverse effects [11,12]. A large ret-
rospective database study of an angiotensin II receptor
blocker (ARB) plus a calcium channel blocker (CCB) in
two-drug SPCs has also shown greater levels of adher-
ence compared with the corresponding free-pill ARB/
CCB regimens [13]. Treatment adherence is an impor-
t a n ti s s u ef o rac h r o n i cd i s e a s es u c ha sh y p e r t e n s i o n ,
with improvements in adherence expected to result in
better long-term clinical outcomes, including reduced
CV and renal morbidity/mortality. This review will
consider the choice of agents for combination therapy
u s i n gt w o - d r u gS P C sa n dt h er ationale for using parti-
cular combinations in patients with hypertension and
renal impairment.
Why should early combination therapy be considered?
Worldwide guidelines recommend combination therapy
as a first-line treatment option for hypertension likely
not to be controlled on monotherapy (e.g. 20/10 mmHg
above target BP) because of evidence showing that only a
minority of patients will achieve and maintain BP goals
on monotherapy [5-8,14]. The recent re-appraisal of the
European guidelines also recommended the preferential
use of SPCs to improve adherence [7].
There are a number of compelling reasons why early
combination therapy should be used in patients with
hypertension (Table 1), including lack of efficacy with
monotherapy, greater BP control and attenuation of side
effects associated with monotherapeutic treatment
[15-20]. In addition, hypertensive patients with comor-
bidities, such as renal disease, might benefit from addi-
tional effects of multiple antihypertensive agents, beyond
those related to BP lowering [10].
What are the preferred drug classes for combination
regimens?
A range of mostly two-drug antihypertensive SPCs is avail-
able [10]. Preferred drug classes for combination regimens
target the renin-angiotensin system (RAS), such as ARBs
and angiotensin-converting enzyme (ACE) inhibitors,
CCBs and diuretics, with selection dependent on indivi-
dual patient factors, including additional CV risk factors
and comorbidities [4,7]. For example, in patients with dia-
betes and high-normal BP or overt hypertension, which
together confer a greater risk of renal damage, combina-
tion therapy with a RAS blocker is preferred because these
agents offer a superior protective effect against initiation
and progression of nephropathy [6]. In patients with renal
disease, antihypertensive therapy should aim to target a
range of markers of renal (and CV) risk, such as serum
creatinine, urine albumin:creatinine ratio, microalbumi-
nuria and proteinuria, usually by RAS blockade, with a
view to reducing and slowing progression to end-stage
renal disease (ESRD) and CV events [6,20]. Microalbumi-
nuria in particular is a marker of global CV risk and is
very common in patients with hypertension [22]. Several
position statements also recommend combined therapy
that includes RAS blockers. The American Society of
Hypertension indicated a preference for RAS blockers in
combination with either a diuretic or CCB, with SPCs
rather than separate agents preferred when convenience
outweighs all other considerations [23]. In addition, the
International Society on Hypertension in Blacks (IHSB)
recommend a RAS blocker-diuretic or CCB combination
in patients with BP > 15/10 mmHg above the target goal
[24]. IHSB guidance extends to recommending combina-
tion with CCB over diuretics where appropriate (in
absence of oedema and/or volume-overload states) due to
superiority for hard clinical outcomes.
Owing to the CV and renal protective effects of RAS
inhibitors, dual RAS blockade is currently under investi-
gation, i.e. ACE inhibitors, ARB combinations and direct
renin inhibitor (DRI) combinations. However studies of
double RAS blockade in high-risk patients have provided
mixed results [25-28] and current evidence therefore,
does not support this therapeutic approach [29].
SPCs containing an ARB may be preferred over those
containing ACE inhibitors. ARBs have superior tolerabil-
ity over ACE inhibitors, which inhibit the degradation of
bradykinin, leading to adverse effects, such as dry cough
and angioedema [30,31]. Several studies have shown
that treatment with ARBs is associated with significantly
lower rates of cough and angioedema versus ACE inhi-
bitors [32,33]. Furthermore, ARBs (in particular telmi-
sartan) are well tolerated in patients who are intolerant
of ACE inhibitors [34]. Due to their superior tolerability,
ARBs may be associated with a higher rate of adherence
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Italy, the rate of discontinuation of the initial single
antihypertensive drug treatment was lower for ARBs
compared with ACE inhibitors (hazard ratio [HR], 0.92;
95% confidence interval [CI], 0.90-0.94) [35].
In addition to increasing the BP-lowering effects of thia-
zides and CCBs, adding a RAS inhibitor may help to
attenuate the unfavourable metabolic side effects of thia-
zide monotherapy [36] and CCB-induced peripheral
oedema [37-40]. CCB-induced peripheral oedema, which
is most likely to occur with dihydropyridine calcium
antagonists[41], is caused by increased capillary pressure
and flow leading to increased permeability and fluid hyper-
filtration [42], appears to be abrogated by post-capillary
dilation and normalisation of hydrostatic pressure induced
by RAS blockers [43]. Although attenuation of CCB-
induced oedema may not as great as that seen with ACE
inhibitors [44], ARBs may still be the preferred choice of
RAS inhibitor due to their superior tolerability.
In addition to providing superior tolerability over ACE
inhibitors, clinical trials have also demonstrated that the
ARBs, in particular telmisartan, provide superior BP low-
ering to ACE inhibitors in the early morning as well as in
the 24-hour, morning, daytime and night-time periods
[45-50].
Hyperlipidaemia is another prevalent condition in
hypertensive patients. Clinical data indicate that ARBs
have no effect on lipid metabolism and are therefore safe
to use in patients with hyperlipidaemia [51,52], supporting
their selection in combined therapy for a broad patient
population. In relation to safety, one analysis suggested
that ARBs may be associated with a modest risk of lung
cancer [53]; however, more complete analyses of current
data have refuted this statement [54,55].
Finally, there is a wealth of data supporting the use of
ARBs in diabetic patients [56], adding to the rationale
for selecting this drug class for combined treatment in
diabetic patients with renal impairment. ARBs and ACE
inhibitors are considered equivalent in patients with
type II diabetes mellitus (T2DM) with microalbumi-
nuria. However, in patients with T2DM with proteinuria
and/or renal insufficiency, ARBs are recommended
because randomised controlled trials have shown that
ARBs delay the progression of nephropathy in these
patients [57]. Furthermore, clinical data suggest that
ARBs may delay development of diabetes in at-risk
patients and therefore prevent CV events in high-risk
patients [56,57].
The other RAS blocker for consideration is aliskiren, a
direct renin inhibitor. SPCs comprising aliskiren with a
CCB or diuretic are also available. Data suggest DRIs and
conventional RAS inhibitors exert similar levels of BP
control [58]. However, unlike ACE inhibitors and ARBs,
there is currently very limited data on the effect of aliski-
r e no nC Va n dr e n a lo u t c o m e s .T h eA L i s k i r e nT r i a li n
Type 2 diabetes Using carDio-renal Endpoints (ALTI-
TUDE) study aimed to assess the effectiveness of alikiren
in reducing CVr and renal events in patients with T2DM
[59], but it was stopped early due to lack of efficacy and
increased side effects, such as non-fatal stroke, renal
complications, hyperkalemia and hypotension. Ongoing
studies will hopefully provide these much-needed data.
As there is currently little evidence to support DRI use in
this patient population, we will not consider it further in
this review.
What are the preferred partners for ARB-based
combinations, and why might telmisartan be a preferred
ARB choice?
Most currently available ARB-based SPCs in Europe com-
bine an ARB with either the thiazide diuretic, hydrochlor-
othiazide (HCTZ), or the CCB, amlodipine (Table 2) [23].
Table 1 Rationale for and potential advantages of early SPC antihypertensive therapy [10,15,16,21]
Rationale:
1. Monotherapy is not effective at reaching and maintaining BP goal in most patients
2. Each difference of 20 mmHg usual SBP or 10 mmHg usual DBP is associated with a two-fold increase in vascular death
3. Using lower doses of each agent reduces the likelihood of adverse events experienced with a single agent used at a higher dose
4. Patients with comorbidities, such as renal disease, might benefit from the non-BP-lowering benefits of antihypertensive agents with
complementary mechanisms of action
Potential advantages:
1. Simplified treatment regimen, which is particularly relevant in older patients with comorbid diseases requiring complicated polytherapy
2. Increased adherence and persistence compared with equivalent free-drug combinations
3. Additive effects on BP control of individual components with different, complementary mechanisms of action
4. Attenuation of recognised adverse events, such as reduced CCB-induced peripheral oedema and diuretic-induced metabolic changes with RAS
blockers
5. Lower costs through increased BP reductions
Abbreviations: BP = blood pressure; CCB = calcium channel blocker; DBP = diastolic blood pressure; RAS = renin-angiotensin system; SBP = systolic blood
pressure; SPC = single-pill combination
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antihypertensive efficacy of ARB/HCTZ combinations
[60-63] and ARB/CCB combinations [40,64-68] compared
with monotherapy.
Currently, there are eight ARBs marketed for hyperten-
sion: azilsartan, candesartan, eprosartan, irbesartan, losar-
tan, olmesartan, telmisartan and valsartan. Owing to their
molecular differences, these agents demonstrate consider-
able variation in their pharmacokinetic and pharmacody-
namic properties, which are likely to affect clinical efficacy
[70]. These differences relate to lipophilicity, volume of
distribution, bioavailability, biotransformation, plasma
half-life, receptor affinity and residence time, as well as
elimination [70,71]. The long-lasting antihypertensive
effects of telmisartan compared with other ARBs are likely
due to this agent having the longest plasma elimination
half-life of approximately 24 hours (Table 3), as well as the
highest affinity for the AT1 receptor [70-72]. As the most
lipophilic of the ARBs, telmisartan also has the highest
volume of distribution, which facilitates tissue/organ pene-
tration (Table 3) [70-73]. Moreover, as a partial agonist of
peroxisome proliferator-activated receptor-gamma, telmi-
sartan may offer advantages in patients with insulin resis-
tance and glucose intolerance, as well as hypertension
[74,75]. These unique characteristics of telmisartan mani-
fest in a number of clinical advantages, such as long-last-
ing BP control and CV protection - consequently
telmisartan has been identified as a gold-standard treat-
ment and has been recommended as a preferred ARB
treatment option [76,77]. Furthermore, telmisartan has
been recognised as an important therapeutic option for
type 2 diabetes patients in the optimisation of CV and
renal prevention [78]. These endorsements nominate tel-
misartan as the preferred ARB choice in combination
therapy.
Several studies have demonstrated the superiority of
telmisartan compared with other ARBs regarding 24-
hour BP-lowering efficacy, particularly in the early
morning period [80-86]. When a smoothness index was
used to evaluate the 24-hour antihypertensive efficacy of
several agents, telmisartan 80 mg had a significantly
higher smoothness index than the ARBs losartan and
valsartan and the ACE inhibitor, ramipril, and was com-
parable with amlodipine [87]. Telmisartan effectively
reduces BP when used alone [32,34,88,89] or in combi-
nation with HCTZ [86,90-94] or amlodipine [37,95,96].
Telmisartan/HCTZ has demonstrated superiority over
losartan/HCTZ in patients with essential hypertension in
terms of 24-hour ambulatory BP, including a BP-lowering
effect during the last 6 hours of the dosing interval
[92,97,98]. In the Study of Micardis
® on Obese/Over-
weight Type-II diabetics with Hypertension (SMOOTH
®),
telmisartan/HCTZ demonstrated significantly greater
reductions in mean ambulatory BP over the entire
24-hour dosing interval and during the last 6 hours com-
pared with valsartan/HCTZ [93]. In two large, placebo-
controlled trials, telmisartan/HCTZ also demonstrated
antihypertensive superiority over valsartan/HCTZ in
patients with stages 1 and 2 hypertension [86,94].
In patients with renal impairment, there are limited
data on the efficacy of telmisartan/HCTZ compared with
placebo, telmisartan monotherapy or other ARB-based
combinations. The Diabetics Exposed to Telmisartan
And enalaprIL (DETAIL
®) study, in which more than
80% of enrolled patients had microalbuminuria, con-
firmed the efficacy of telmisartan in combination with a
diuretic [99]. Switching patients with poorly controlled
hypertension and mild-to-moderate chronic kidney dis-
ease from high-dose ARBs to telmisartan 40 mg/HCTZ
12.5 mg provided additional BP reductions and reduced
urinary protein excretion, suggesting the combination is
effective in this patient population [100]. Telmisartan/
HCTZ has also demonstrated excellent tolerability. A ret-
rospective safety analysis of 50 studies that evaluated tel-
misartan either as monotherapy or combined with HCTZ
c o n f i r m e dt h a tt h ea d d i t i o no fH C T Zd i dn o th a v ea
negative impact on the excellent tolerability profile of tel-
misartan, which is comparable with placebo [101]. Simi-
lar tolerability profiles have been reported for other ARB/
HCTZ combinations [102-104].
Studies have also confirmed the therapeutic advantages
of telmisartan and amlodipine combined therapy versus
the monotherapies on reaching and maintaining BP goals
in hypertensive patients [37,95,96,105]. Subgroup analysis
of a trial conducted in patients with moderate-to-severe
hypertension demonstrated that the telmisartan/amlodi-
pine combination yielded reductions in mean seated
trough systolic BP (SBP)/diastolic BP of up to -25.7/-19.5
mmHg in patients with mild renal impairment (estimated
glomerular filtration rate [GFR] ≥ 60 ml/min/1.73 m
2)a n d
-26.5/-20.8 mmHg in patients with moderate-to-severe
renal impairment (estimated GFR < 60 ml/min/1.73 m
2)
[106]. The BP goal of < 140/90 mmHg was achieved in up
Table 2 Currently authorised ARB-based two-drug SPC
antihypertensive therapy in Europe in 2011 [69]
ARB HCTZ combination CCB combination
Telmisartan ✓✓
Valsartan ✓✓
Olmesartan ✓✓
Losartan ✓
Irbesartan ✓
Candesartan
Eprosartan
Azilsartan
Abbreviations: ARB = angiotensin II receptor blocker; CCB = calcium channel
blocker; HCTZ = hydrochlorothiazide; SPC = single-pill combination
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to 75.0% of those with moderate-to-severe renal impair-
ment [106]. In a separate 8-week, randomised, double-
blind trial in patients with T2DM and stages 1 or 2 hyper-
tension (SBP > 150 mmHg), the telmisartan/amlodipine
combination was superior as initial therapy compared with
amlodipine 10 mg [107]. The BP goal of 140/90 mmHg
was reached by 71.4% of patients treated with the telmisar-
tan/amlodipine SPC compared with 53.8% of those treated
with amlodipine 10 mg alone. For the more stringent BP
goal of ≤ 130/80 mmHg, these rates were 36.4% and 17.9%
for the telmisartan/amlodipine and amlodipine 10 mg
groups, respectively.
Further to the beneficial outcomes on BP, the addition
of telmisartan has been shown to reduce the incidence of
peripheral oedema induced by amlodipine [37]. This effect
is thought to be mediated by the reduction of CCB-
induced renal hyperfiltration and proteinuria - in a recent
clinical study, where a 70% decrease in the urine albumin-
to-creatinine ratio (UACR) was seen in those patients trea-
ted with a telmisartan and amlodipine combination com-
pared with amlodipine monotherapy (Figure 1) [107].
What is the preferred combination therapy for patients
with renal impairment?
RAS blockers are the recommended choice of treatment
for patients with renal impairment [108]. When faced with
hypertensive patients with evidence of renal damage, the
physician should consider the use of an ARB-based SPC,
for tolerability reasons. Choices are numerous but often
result in a choice between ARB/CCB and ARB/HCTZ,
and it is therefore prudent to consider the evidence for
these two combination types in patients with renal
impairment.
In a randomised, open-label study that compared
urinary albumin excretion in 207 hypertensive patients
during treatment with the ARB, olmesartan, in combina-
tion with either HCTZ or the CCB, azelnidipine, ARB/
HCTZ decreased UACR significantly more. This was
clearly associated with greater reductions in night-time
SBP, suggesting that the differential renal effects were
due to differences in BP lowering [109]. In the Avoiding
Cardiovascular events through COMbination therapy in
Patients LIving with Systolic Hypertension (ACCOM-
PLISH) trial involving 11,506 patients, treatment with
the ACE inhibitor, benazepril, combined with amlodi-
pine was associated with a significant risk reduction for
renal disease progression, as well as CV disease events,
compared with benazepril/HCTZ in hypertensive
Table 3 Pharmacokinetic properties of ARBs [49,50,79]
tmax(h) Bioavailability (%) T1/2
(h)
Vd
(L)
Interaction with food Hepatic elimination (%)
Candesartan 3.0-5.0 42 9-13 0.13 (L/kg) No 67
Eprosartan 2.0-6.0 13 5-7 308 No 90
Irbesartan 1.0-2.0 60-80 12-20 53-93 No 80
Losartan 1.0 (3.0-4.0)
1 33 2 (4-6)
1 34 (12)
1 No 60
Olmesartan 1.4-2.8 26
2 11.8-14.7 15-20 No 51-66
3
Telmisartan 1 43 24 500 No > 98
4
Valsartan 2 23 7 17 No 83
Azilsartan 1.5-3.0 60 11 16 No 55
Abbreviations: ARB = angiotensin II receptor blocker; t1/2 = terminal elimination half-life; tmax = time to maximum plasma concentration; Vd = volume of
distribution
1 Values in parentheses are for the active metabolite of losartan
2 For olmesartan medoxomil
3 Based on urinary recovery rate for intravenous olmesartan
4 Faecal recovery for telmisartan
Figure 1 The renal effects of amlodipine and telmisartan/
amlodipine SPC. UACR changes after 8 weeks’ treatment with the
telmisartan/amlodipine SPC or amlodipine monotherapy in diabetic,
hypertensive patients [107]. Abbreviations: SPC = single-pill
combination; T/A = telmisartan/amlodipine; UACR = urine albumin-
to-creatinine ratio.
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patients experienced chronic kidney disease progression
in the benazepril/amlodipine group compared with 3.7%
in the benazepril/HCTZ group (HR, 0.52; 95% CI, 0.41-
0.65; p < 0.0001) [110]. Around 18% of patients enrolled
in the ACCOMPLISH trial had an estimated GFR of <
60 ml/min/1.73 m
2, suggestive of renal disease and 6.1%
were defined as having renal disease based on serum
creatinine levels or the presence of macroalbuminuria
[111]. The differences in the renoprotective effects of
the two combinations are unlikely to be due to differ-
ences in the level of BP control because 24-hour ambu-
latory BP control was comparable in the two treatment
arms [112,113]. The significantly greater renoprotective
effects provided by the RAS blocker combined with
amlodipine rather than HCT Za r em o r el i k e l yd u et o
metabolic or haemodynamic properties of the specific
combination [112,113].
The view that thiazide diuretics reduce GFR and have
lower efficacy in the renally impaired may also impact
the efficacy and renoprotective outcome of combined
therapy. Consequently, loop diuretics rather than thia-
zide diuretics are specifically recommended in patients
with ESRD/proteinuria because they more readily
increase diuresis at lower GFRs [6,7].
These findings suggest that a RAS blocker, combined
with a CCB rather than HCTZ, may be the combination
of choice for high CV risk hypertensive patients, such as
those with coronary artery disease with or without stable
angina, patients with a metabolic risk profile (e.g. dia-
betes, obesity or metabolic syndrome) and, in particular,
those with renal disease. In addition, it should be noted
that some data suggests thiazide diuretics may impair
glucose homeostasis and that treatment is associated
with a greater incidence of diabetes compared with
other antihypertensives [114,115]. Furthermore, com-
pared with olmesartan/HCTZ, olmesartan/amlodipine
treatment was associated beneficial metabolic and
inflammatory effects and a lower-risk of new onset dia-
betes in non-diabetic patients with metabolic syndrome
[116]. These data reinforce the suggestion that ARB/
CCB combinations may be a preferred treatment combi-
nation, especially in patients with concomitant metabolic
disorders, such as diabetes.
The renoprotective effects of ARBs and ACE inhibi-
tors are mediated via their ability to block RAS activity
[117]. This makes RAS blockers the treatment of choice
in patients with diabetic kidney disease and non-diabetic
kidney disease with proteinuria [108]. For the ARBs, evi-
dence for guideline recommendations came from a
number of clinical trials (predominantly in patients with
c h r o n i ck i d n e yd i s e a s e )t h a ts h o w e dA R B st ob er e n o -
protective, independent of their BP-lowering effects
(Table 4). For example, the IRbesartan in patients with
type II diabetes and MicroAlbuminuria (IRMA2) study
demonstrated that irbesartan, added to other antihyper-
tensive agents, could prevent the development of dia-
betic nephropathy in hypertensive patients with T2DM
and persistent microalbuminuria [118]. Also in patients
with T2DM, the Irbesartan in Diabetic Nephropathy
T r i a l( I D N T )d e m o n s t r a t e dt h a ti r b e s a r t a ns i g n i f i c a n t l y
reduced the risk of the composite primary endpoint of a
doubling of serum creatinine, ESRD or death compared
with placebo and amlodipine [119]. Losartan also
demonstrated renoprotective effects in the Angiotensin
II Antagonist Losartan (RENAAL) study [120]. In addi-
tion, the MicroAlbunuria Reduction with VALsartan
(MARVAL) study showed greater reduction in urinary
albumin excretion rate with valsartan than amlodipine
for the same BP reduction [106,121].
In hypertensive patients, telmisartan has demonstrated
renoprotective effects. In the DETAIL
® study, telmisartan
was not inferior to the ACE inhibitor, enalapril, in pro-
viding long-term renoprotection as measured by change
in GFR in patients with T2DM [99]. The inVestigate the
efficacy of telmIsartan versus VALsartan in hypertensive
type II DIabetic patients with overt nephropathy
(VIVALDI
®) study demonstrated that telmisartan and
valsartan provided similar levels of renoprotection in
T2DM patients with overt nephropathy, as measured by
changes in 24-hour urinary protein excretion rate, 24-
hour urinary albumin excretion rate and estimated GFR
[124]. In contrast, telmisartan demonstrated superior effi-
cacy in reducing proteinuria compared with losartan,
despite similar BP reductions in hypertensive T2DM
patients with overt nephropathy [122].
Telmisartan has also shown efficacy in non-hyperten-
sive patients. Based on the findings of the ONgoing Tel-
misartan Alone and in combination with Ramipril
Global Endpoint Trial (ONTARGET
®), which rando-
mised 25,620 patients with vascular disease or diabetes
with end-organ damage, to receive either telmisartan or
the reference standard ACE inhibitor, ramipril, or a
combination of the two agents [32], telmisartan is the
only ARB with an indication for CV prevention inde-
pendent of BP, including diabetes patients with estab-
lished end organ damage such as renal disease.
ONTARGET
® demonstrated that the two agents were
equally effective in reducing the primary composite out-
come of CV death, myocardial infarction, stroke or hos-
pitalisation due to heart failure (relative risk, 1.01; 95%
CI, 0.94-1.09), but that telmisartan was better tolerated
than ramipril [32]. Previously, ramipril had demon-
strated CV prevention properties in the Heart Outcomes
Prevention Evaluation (HOPE) study [125]. Evidence
from the ONTARGET
® and the Telmisartan Rando-
mized AssessmeNt Study in ACE-I iNtolerant subjects
with cardiovascular Disease (TRANSCEND
®)t r i a l sa l s o
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sartan [126-128].
Guidelines recommend RAS blockers, such as ACE inhi-
bitors and ARBs, as the treatment of choice for patients
with renal impairment [108]. Other antihypertensives may
be added if BP is not controlled. In addition, the issue of
tolerability and adverse events, particularly the occurrence
of ACE inhibitor-induced cough, supports the use of
ARBs rather than ACE inhibitors in combination therapy
in patients with renal impairment [129].
Summary and conclusion
It is now accepted that most hypertensive patients will
not reach and maintain BP goal on monotherapy. There-
fore, initial combination therapy is being increasingly
used and recommended by guidelines, particularly for
patients with CV risk factors, such as a history of prior
CV events, comorbid diabetes mellitus, microalbuminuria
and evidence of organ damage, such as renal disease [7].
Guidelines also recommend the use of SPCs over free-
drug combinations due to their improved adherence [7].
In patients with evidence of renal disease or in those with
a greater risk of developing renal disease, such as those
with diabetes and high-normal BP or overt hypertension,
guidelines clearly recommend RAS blocker-based combi-
nation therapy due to superior renoprotective effects
compared with other classes of antihypertensive agent
[7]. Combinations containing an ARB rather than an
A C Ei n h i b i t o rm a yb ep r e f e r r e db e c a u s eA R B sa r ea s s o -
ciated with superior tolerability, which may lead to
improved adherence. In patients with T2DM with protei-
nuria and/or renal insufficiency, ARB-based treatment is
recommended because these agents delay the progression
of nephropathy (Table 5).
Two-drug, ARB-based SPCs are available in combina-
tion with either HCTZ or amlodipine. Telmisartan, a
long-acting ARB with superior 24-hour BP-lowering effi-
cacy compared with several other ARBs, and the only ARB
with an indication for the prevention of CV disease pro-
gression, is available in two SPC formulations: telmisartan/
HCTZ and telmisartan/amlodipine. Reaching a decision
about which of these to use in a hypertensive patient with
evidence of renal impairment is difficult in the absence of
clinical trial data. However, evidence from the ACCOM-
PLISH trial supports the use of a RAS blocker combined
with a CCB, rather than HCTZ, for high CV risk hyperten-
sive patients, such as those with coronary artery disease
with or without stable angina, patients with a metabolic
Table 4 Results of clinical trials indicating the renoprotective nature of ARBs
Study Patients n Treatment Duration Principle findings
AMADEO
®
[122]
Hypertension and diabetic
nephropathy
860 Telmisartan or
losartan
52 weeks Telmisartan was superior to losartan in reducing proteinuria
CALM [25] Type 2 diabetes with
hypertension and
microalbuminuria
199 Candesartan,
lisinopril or
both
24 weeks Candesartan was as effective as lisinopril in reducing UACR. Combined
treatment was associated with a greater reduction in UACR than
monotherapeutic treatment (statistically significant versus candesartan
monotherapy)
DETAIL
®
[99]
Hypertension, Type 2
diabetes and early
nephropathy
250 Telmisartan or
enalapril
5 years Telmisartan was not inferior to enalapril in providing long-term
renoprotection
IDNT [119] Hypertension and diabetic
nephropathy
1715 Irbesartan,
amlodipine or
placebo
Mean 2.6
years
Irbesartan was superior to amlodipine and placebo in preventing the
primary composite end point of: a doubling of the base-line serum
creatinine concentration, the development of ESRD, or death from any
cause. This was independent of BP
IRMA 2
[118]
Hypertension, type 2
diabetes and
microalbuminuria
590 Irbesartan or
Placebo
2 years Irbesartan was superior to placebo in preventing diabetic nephropathy
MARVAL
[121]
Diabetic nephropathy with
and without hypertension
332 Valsartan or
amlodipine
24 weeks Valsartan was superior to amlodipine in reducing microalbuminuria
RENAAL
[120]
Diabetic nephropathy 1513 Losartan or
placebo
Mean 3.4
years
Losartan was superior to placebo in preventing increases in UACR and
progression to ESRD. There was no difference in mortality
ROADMAP
[123]
Type 2 diabetes with
normoalbuminuria
4449 Olmesartan or
placebo
Median
3.2 years
Olmesartan delayed the time to onset of microalbuminuria (statistical
significance lost on adjustment for blood pressure difference)
VIVALDI
®
[124]
Hypertension and diabetic
nephropathy
885 Telmisartan or
valsartan*
52 weeks Telmisartan and valsartan provided similar renoprotection
Abbreviations: AMADEO
® = A trial to compare telMisartan 40 mg titrated to 80 mg versus losArtan 50 mg titrated to 100 mg in hypertensive type 2 DiabEtic
patients with Overt nephropathy; ARB = angiotensin II receptor blocker; BP = blood pressure; CALM = CAndesartan and Lisinopril Microalbuminuria; DETAIL
® =
Diabetics Exposed to Telmisartan And enalaprIL study; ESRD, end-stage renal disease; IDNT = Irbesartan type II Diabetic Nephropathy Trial; IRMA2 = IRbesartan in
patients with type 2 diabetes and MicroAlbuminuria; MARVAL = MicroAlbuminuria Reduction with VALsartan trial; RENAAL = Reduction of Endpoints in NIDDM
with the Angiotensin II Antagonist Losartan; ROADMAP = Randomized Olmesartan And Diabetes Microalbuminuria Prevention; UACR = urine albumin:creatinine
ratio; VIVALDI
® = A trial to inVestigate the efficacy of telmIsartan versus VALsartan in hypertensive type 2 DIabetic patients with overt nephropathy.
*Additional hypertensive treatment was allowed in VIVALDI
®.
Mallat Cardiovascular Diabetology 2012, 11:32
http://www.cardiab.com/content/11/1/32
Page 7 of 12risk profile and particularly for those with renal disease
[110,111]. Data demonstrating beneficial metabolic and
inflammatory effects with ARB/CCB combined therapy
(versus ARB/HCTZ therapy), may also lead to the pre-
ferred use of RAS blocker-CCB combinations to achieve
further BP reductions whilst avoiding further metabolic
disturbances and protecting the kidneys from further
damage [116]. However, in hypertensive patients at
increased CV risk requiring an antihypertensive agent that
specifically reduces blood volume, the combination of an
ARB to protect the kidneys and a thiazide diuretic might
be the treatment of choice.
There is a wide range of antihypertensive combina-
tions to choose from and selecting the most appropriate
treatment regimen for an individual patient with, or at
risk of, renal impairment must depend on a number of
considerations: careful review of the patient; the phar-
macokinetic/pharmacodynamics properties of the avail-
able treatment agents; and the available clinical evidence
from outcome studies.
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